Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Breast Neoplasms 8Triple Negative Breast Neoplasms 5Ovarian Neoplasms 4Endometrial Neoplasms 3Thyroid Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Thrombocytosis 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1

Interventions

tucatinib 1temsirolimus 1pembrolizumab 1niraparib 1lenvatinib 1atezolizumab 1Valproic Acid 1Trastuzumab 1Tissue Banks 1Sirolimus 1Immunoglobulin G 1Fulvestrant 1Doxycycline 1Disulfides 1Cetuximab 1Capecitabine 1Blood Specimen Collection 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × lenvatinib × Breast × Clear all
NCT02915172 2017-06-26

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Withdrawn
BreastGenitourinary

Breast Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡